Get started
Author

Nasséra Chalabi

Resveratrol and breast cancer chemoprevention: Molecular mechanisms
2005 · Ludovic Le Corre, N. Chalabi, et al. · Molecular Nutrition & Food Research · 162
Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact
2014 · J.M. Nabholtz, C. Abrial, et al. · Annals of Oncology · 126
Can pathologic complete response (pCR) be used as a surrogate marker of survival after neoadjuvant therapy for breast cancer?
2015 · Qian Wang-Lopez, Nassera Chalabi, et al. · Critical Reviews in Oncology/Hematology · 95
Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study
2024 · Alwin Krämer, Tilmann Bochtler, et al. · The Lancet · 94
Genistein and daidzein act on a panel of genes implicated in cell cycle and angiogenesis by Polymerase Chain Reaction arrays in human prostate cancer cell lines
2010 · Nadège Rabiau, Myriam Kossaï, et al. · Cancer Epidemiology · 77
Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer
2015 · J.M. Nabholtz, N. Chalabi, et al. · International Journal of Cancer · 60
PDF
Gene Signature of Breast Cancer Cell Lines Treated with Lycopene
2006 · Nasséra Chalabi, Laëtitia Delort, et al. · Pharmacogenomics · 57
The effects of lycopene on the proliferation of human breast cells and BRCA1 and BRCA2 gene expression
2004 · N Chalabi, L Le Corre, et al. · European Journal of Cancer · 57
DNA repair gene ERCC2, XPC, XRCC1, XRCC3 polymorphisms and associations with bladder cancer risk in a French cohort.
2008 · Luc Fontana, Rémy Bosviel, et al. · PubMed · 53
Effects of resveratrol on the expression of a panel of genes interacting with the BRCA1 oncosuppressor in human breast cell lines
2004 · Ludovic Le Corre, Pierre Fustier, et al. · Clinica Chimica Acta · 52
Resveratrol increases BRCA1 and BRCA2 mRNA expression in breast tumour cell lines
2003 · P Fustier, L Le Corre, et al. · British Journal of Cancer · 50
PDF
Central adiposity as a major risk factor of ovarian cancer.
2009 · Laetitia Delort, Fabrice Kwiatkowski, et al. · PubMed · 48
DNA repair gene ERCC2 polymorphisms and associations with breast and ovarian cancer risk
2008 · Dominique Bernard-Gallon, Rémy Bosviel, et al. · Molecular Cancer · 45
PDF
Expression profiling by whole-genome microarray hybridization reveals differential gene expression in breast cancer cell lines after lycopene exposure
2007 · Nasséra Chalabi, Samir Satih, et al. · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · 44
Gene Expression Profiling of Breast Cancer Cell Lines in Response to Soy Isoflavones Using a Pangenomic Microarray Approach
2010 · Samir Satih, Nasséra Chalabi, et al. · OMICS A Journal of Integrative Biology · 42
Association between genetic polymorphisms and ovarian cancer risk.
2008 · Laetitia Delort, Nasséra Chalabi, et al. · PubMed · 39
Comparative clinical and transcriptomal profiles of breast cancer between French and South Mediterranean patients show minor but significative biological differences.
2008 · N Chalabi, D J Bernard-Gallon, et al. · PubMed · 38
Soya phytonutrients act on a panel of genes implicated withBRCA1andBRCA2oncosuppressors in human breast cell lines
2006 · Bertrand Caëtano, Ludovic Le Corre, et al. · British Journal Of Nutrition · 33
PDF
Baseline mutational profiles of patients with carcinoma of unknown primary origin enrolled in the CUPISCO study
2023 · C.B. Westphalen, J. Federer-Gsponer, et al. · ESMO Open · 24
Differential Expression of Genes Induced by Resveratrol in Human Breast Cancer Cell Lines
2006 · Ludovic Le Corre, Nasséra Chalabi, et al. · Nutrition and Cancer · 22
LBA16 Primary analysis of efficacy and safety in the CUPISCO trial: A randomised, global study of targeted therapy or cancer immunotherapy guided by comprehensive genomic profiling (CGP) vs platinum-based chemotherapy (CTX) in newly diagnosed, unfavourable cancer of unknown primary (CUP)
2023 · L. Mileshkin, T. Bochtler, et al. · Annals of Oncology · 19
PDF
Panitumumab in combination with FEC 100 (5-fluorouracil, epidoxorubicin, cyclophosphamide) followed by docetaxel (T) in patients with operable, triple-negative breast cancer (TNBC): Preliminary results of a multicenter neoadjuvant pilot phase II study.
2011 · J. Nabholtz, B. Weber, et al. · Journal of Clinical Oncology · 17
Risk factors for early age at breast cancer onset--the "COSA program" population-based study.
2007 · Laetitia Delort, Fabrice Kwiatkowski, et al. · PubMed · 10
Evolution in the real-world therapeutic strategies in more than 20,000 women with breast cancer having received human epidermal growth factor receptor 2–targeted treatments: Results from the french personalized reimbursement model database (2011–2018)
2020 · Paul Cottu, Bruno Coudert, et al. · European Journal of Cancer · 9
PDF
Nutrigenomics and Antioxidants
2007 · Nasséra Chalabi, Dominique J Bernard-Gallon, et al. · Personalized Medicine · 9
Works count: 57
Citation count: 1,342
H-index: 20
I10-index: 23
Year
Topic
Type